Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Jackson Creek Investment Advisors LLC

Jackson Creek Investment Advisors LLC lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 59.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,284 shares of the biopharmaceutical company's stock after selling 42,465 shares during the period. Jackson Creek Investment Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $710,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Castlekeep Investment Advisors LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $37,494,000. Bank of America Corp DE boosted its holdings in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after buying an additional 913,843 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Catalyst Pharmaceuticals by 131.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after acquiring an additional 396,506 shares during the period. Vanguard Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock worth $175,957,000 after purchasing an additional 390,116 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter worth $6,887,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of "Buy" and an average target price of $32.83.

Catalyst Pharmaceuticals Price Performance

CPRX traded down $0.11 on Tuesday, reaching $20.90. The company's stock had a trading volume of 1,311,465 shares, compared to its average volume of 1,148,408. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of 13.31, a price-to-earnings-growth ratio of 0.86 and a beta of 0.66. Catalyst Pharmaceuticals, Inc. has a 1 year low of $15.34 and a 1 year high of $26.58. The business's 50 day moving average is $23.12 and its 200 day moving average is $22.89.

Insider Activity

In related news, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider owned 41,081 shares of the company's stock, valued at $1,085,360.02. The trade was a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the transaction, the insider owned 68,873 shares of the company's stock, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 247,924 shares of company stock valued at $5,879,369 in the last quarter. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.